GLP-1 Drugs Win New FDA Uses as Studies Link Them to 41% Lower Cancer Risk
Updated
Updated · TODAY · Aug 31
GLP-1 Drugs Win New FDA Uses as Studies Link Them to 41% Lower Cancer Risk
3 articles · Updated · TODAY · Aug 31
Summary
Eli Lilly’s Mounjaro won FDA approval on Aug. 28 to cut heart attack, stroke and cardiovascular-death risk in adults with Type 2 diabetes, the latest expansion for GLP-1 medicines beyond weight loss and glucose control.
Researchers say the drugs’ broad reach may stem from GLP-1 receptors across the body and anti-inflammatory effects, helping explain benefits already seen in heart disease, sleep apnea, kidney disease and fatty liver disease.
Newer evidence is widening interest further: a 2026 study linked GLP-1 use to a 41% lower risk of obesity-related cancers, while separate research found women with excess weight were about 30% less likely to develop breast cancer.
Doctors are also studying whether GLP-1s could help with addiction, fertility and healthy aging, but they say prescribing them preventively to otherwise healthy people remains premature without stronger evidence.
Safety still tempers the enthusiasm: 11% of U.S. adults use GLP-1s for weight loss alone, yet gastrointestinal side effects are common and rarer risks include pancreatitis, gallbladder problems and possible thyroid tumors.